In simple words: This code tracks whether a quantitative measurement of specific proteins (like estrogen or progesterone receptors) in breast cancer cells has been done, excluding HER2 protein, using a laboratory method called immunohistochemistry (IHC). This test helps determine the type and treatment of breast cancer.

Quantitative non-HER2 immunohistochemistry (IHC) evaluation of breast cancer (eg, testing for estrogen or progesterone receptors [ER/PR]) performed (PATH).

Example 1: A 55-year-old female diagnosed with invasive ductal carcinoma undergoes surgery. A sample of the tumor is sent for IHC analysis, which includes quantitative assessment of ER and PR expression to guide treatment decisions like hormone therapy., A 60-year-old woman has a biopsy showing ductal carcinoma in situ. IHC testing is performed, and ER/PR levels are quantitatively measured. This helps understand the tumor characteristics and assess responsiveness to endocrine therapy if needed., A 48-year-old female with a breast lump undergoes a core needle biopsy. The pathology report indicates invasive lobular carcinoma. IHC is performed, and quantitative results for ER and PR are recorded. This information is used to personalize treatment options, which may include hormonal therapy.

Pathology report documenting the quantitative results of IHC for ER and PR, type of breast cancer, and the date the test was performed.

** This is a Category II code used for performance measurement, not for billing purposes. It is optional and does not have an associated relative value unit (RVU). It tracks specific services related to quality patient care.